A cure for aggressive lymphoma exists. Most patients never get it.

Chemotherapy stops working for about half of patients with aggressive lymphoma. There is a therapy that can cure many of them after that point, and only about two in ten eligible patients ever receive it. Manali Kamdar, who leads lymphoma services in Colorado, and Paolo Strati, who treats lymphoma at MD Anderson, explain what stands between a relapse and a referral, and what the treatment actually asks of a patient.

⏱️ Chapters:
0:00 Introduction
0:34 From wanting to be a dancer to running a lymphoma program
2:22 Why an Italian physician retrained from scratch in the U.S.
3:49 What happens when chemotherapy stops working
4:52 Why your T cells stop recognizing the cancer
6:12 Approved for nearly a decade, reaching 2 in 10 patients
6:42 What a Washington summit found blocking access
7:24 The two-week authorization while the cancer grows
8:32 A line in the neck, then a nerve-wracking wait
10:23 Day zero, and the month spent living near the center
12:15 Why a CAR-T referral never enters the office pathway
12:49 The transplant myth, and the 89-year-old who disproves it
14:10 Why googling CAR-T talks patients out of it
15:51 Why the referral should start at diagnosis
18:05 Take home messages

About this episode:
Manali Kamdar is clinical director of lymphoma services at the University of Colorado Anschutz, and Paolo Strati is an associate professor of lymphoma and myeloma at MD Anderson Cancer Center. Both treat aggressive large B-cell lymphoma, and Kamdar says 40 to 50 percent of those patients used to die of the disease before CAR-T cell therapy began salvaging them. Nearly a decade after FDA approval, they say only about two in ten eligible patients reach it. They helped lead a stakeholder summit convened in Washington, D.C. by the Lymphoma Research Foundation to find out why, and the answers were logistical rather than scientific. Referral knowledge is thin, payer authorization runs about two weeks while the cancer grows, manufacturing takes seventeen days to a month, few centers are accredited, and not every patient has a caregiver who can travel and stay. Strati walks the patient journey in order, from the line placed in the neck to collect cells through bridging treatment, three days of lymphodepleting chemotherapy, and the weeks spent living near the center afterward. Kamdar takes apart the belief that CAR-T eligibility works like transplant eligibility, describing an 89-year-old she brought through it whose only complaint was boredom. Their closing argument is that success should be measured by who can deliver this therapy, not by who happens to receive it.

🤝 This episode is brought to you by ModMed:
Welcome to your new AI-Powered Practice from ModMed. We're transforming specialty care by embedding AI Assistants across your entire workflow. Our all-in-one platform of EHR, patient engagement, practice management, and RCM helps reduce repetitive work while keeping you firmly in control. Trained on de-identified data from nearly a billion patient encounters, this isn't just smarter software. It's a new way of working for specialty medicine, more efficient and more connected to the patient experience. Start building your AI-Powered Practice at modmed.com.

➡️ VISIT SPONSOR: https://www.modmed.com/

🤝 Partner with me on the KevinMD platform:
With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Let's work together to tell your story.

➡️ PARTNER WITH KEVINMD: https://kevinmd.com/influencer
➡️ SUBSCRIBE TO THE PODCAST: https://www.kevinmd.com/podcast
➡️ RECOMMENDED BY KEVINMD: https://www.kevinmd.com/recommended

#Lymphoma #CARTCellTherapy #CancerTreatment